Delivery Order SPE2DB20D1004-SPE2DB25FNKCC
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order valued at $11,862.80, with an ultimate completion date of August 15, 2025. The order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $7,389.26. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron Orally Disintegrating Tablets 4mg in a quantity of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $52,217.75 and an ultimate completion date of September 10, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $4,930.33 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with an ultimate completion date of August 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,730.96 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg on August 14, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers. This delivery order...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron Orally Disintegrating Tablets 4mg in a quantity of 30 tablets. This is a firm fixed price delivery order valued at $6,666.32 with an ultimate completion date of September 11, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $1,961.44. This firm fixed price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The work will be performed at...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNKCCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,179.85 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, non-set-aside contract carries a firm fixed price and is scheduled for completion by August 14, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor and healthcare solutions provider. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and healthcare commodities to support military healthcare systems and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. Ondansetron, an antiemetic commonly used in medical and surgical settings, represents one element of the extensive pharmaceutical portfolio delivered under this framework agreement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 8/13/25 |